Quick Answer
Pyxis Oncology, Inc. reported Total Revenue of $13.86 million for fiscal year 2025.
Pyxis Oncology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $13.86M -14.2% |
$16.15M | — | — | — | — |
| Net Income | -$79.62M -3.0% |
-$77.33M -4.8% |
-$73.79M +38.9% |
-$120.72M -58.9% |
-$75.97M -492.3% |
-$12.83M |
| Diluted EPS | -$1.28 +3.0% |
-$1.32 +28.6% |
-$1.85 +49.3% |
-$3.65 +59.2% |
-$8.95 | — |
| Total Assets | $91.52M -41.8% |
$157.18M -9.5% |
$173.73M -17.8% |
$211.38M -24.5% |
$280.02M +2658.6% |
$10.15M |
| Cash and Equivalents | $15.42M -20.8% |
$19.47M +101.5% |
$9.66M -94.6% |
$179.29M -34.7% |
$274.74M +3300.2% |
$8.08M |
| Stockholders Equity | $53.41M -55.8% |
$120.75M -3.9% |
$125.70M -21.8% |
$160.82M -38.5% |
$261.31M +1770.3% |
-$15.64M -444.4% |
| R&D Expense | $73.70M +25.4% |
$58.75M +18.5% |
$49.59M -42.4% |
$86.13M +68.7% |
$51.05M +464.3% |
$9.05M |
| Operating Income | -$84.42M +5.6% |
-$89.46M -8.8% |
-$82.20M +33.4% |
-$123.48M -77.1% |
-$69.72M -440.7% |
-$12.89M |
| Shares Outstanding | 62.69M +4.5% |
59.97M +34.0% |
44.75M +28.0% |
34.96M +8.5% |
32.22M +2399.2% |
1.29M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $2.82M | — | -82.5% |
| Net Income | September 30, 2025 | -$22.00M | -3.8% | -19.9% |
| Diluted EPS | September 30, 2025 | -$0.35 | +0.0% | -16.7% |
| Total Assets | September 30, 2025 | $105.60M | -45.9% | -14.3% |
| Cash and Equivalents | September 30, 2025 | $8.92M | -26.0% | -16.9% |
| Stockholders Equity | September 30, 2025 | $68.78M | -55.2% | -21.5% |
| R&D Expense | September 30, 2025 | $17.81M | +0.4% | +3.9% |
| Operating Income | September 30, 2025 | -$23.46M | +1.2% | -18.8% |
| Shares Outstanding | September 30, 2025 | 62.15M | +4.5% | +0.2% |
- Pyxis Oncology, Inc. reported Total Revenue of $13.86 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed a decrease of -14.2% in Total Revenue compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Net Income of -$79.62 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed a decrease of -3.0% in Net Income compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Diluted EPS of $1.28 per share (loss) for fiscal year 2025.
- Pyxis Oncology, Inc. showed an increase of +3.0% in Diluted EPS compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Total Assets of $91.52 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed a decrease of -41.8% in Total Assets compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Cash and Equivalents of $15.42 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed a decrease of -20.8% in Cash and Equivalents compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Stockholders Equity of $53.41 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed a decrease of -55.8% in Stockholders Equity compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported R&D Expense of $73.70 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed an increase of +25.4% in R&D Expense compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Operating Income of -$84.42 million for fiscal year 2025.
- Pyxis Oncology, Inc. showed an increase of +5.6% in Operating Income compared to the prior fiscal year.
- Pyxis Oncology, Inc. reported Shares Outstanding of 62.69 million shares for fiscal year 2025.
- Pyxis Oncology, Inc. showed an increase of +4.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: